Innophore’s vision is to identify and develop high-value industrial and therapeutic enzymes and more efficient, environmentally friendly ‘green’ chemical production processes and novel biosimilars for medical treatments, including contributions to drug repurposing and side-effect prediction using our 3D point-cloud technology.
High-performance supercomputing is our daily business. Our clusters use about 6500 CPUs to run your experiments. Furthermore, we can deploy the experiments in the cloud. For this, we use Amazon Web Service (AWS) and Google Cloud.
We solve problems in a collaborative effort involving experts from different fields. This is also represented in our publication portfolio. Both established and young researchers contribute to our success.
We solve problems in a collaborative effort involving experts from different fields. This is also represented in our publication portfolio. Both established and young researchers contribute to our success.
In 2018, Innophore started as just a vision. Today, Innophore’s growing interdisciplinary team is proof that this vision has become a reality. Molecular biologists, biotechnologists, (bio)chemists, physicists, machine-learning experts, and computer scientists work together to steadily improve Innophore’s technology and find a solution to any challenge that arises.
Innophore GmbH is a spin-off company of acib GmbH and the University of Graz and was supported as a start-up project by Science Park Graz GmbH in the framework of the AplusB program.
Innophore GmbH is supported by the strategic investor EOSS Industries GmbH.
List of Publications